As of May 24, 2025, Enlabs AB's estimated intrinsic value ranges from $3.53 to $24.14 per share, depending on the valuation methodology applied.
| Valuation Method | Fair Value (USD) | Implied Upside/Downside |
|---|---|---|
| Discounted Cash Flow (10Y) | $11.90 | -77.6% |
| Discounted Cash Flow (5Y) | $8.00 | -84.9% |
| Dividend Discount Model (Multi-Stage) | $11.49 | -78.4% |
| Dividend Discount Model (Stable) | $24.14 | -54.5% |
| Earnings Power Value | $3.53 | -93.4% |
Is Enlabs AB (NLAB.ST) undervalued or overvalued?
With the current market price at $53.10, the stock appears to be significantly overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Enlabs AB's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
| WACC Component | Low | High |
|---|---|---|
| Long-term bond rate | 2.3% | 2.8% |
| Equity market risk premium | 4.7% | 5.7% |
| Adjusted beta | 0.55 | 0.64 |
| Cost of equity | 5.4% | 7.5% |
| Cost of debt | 5.0% | 5.0% |
| Tax rate | 2.4% | 6.3% |
| Debt/Equity ratio | 0 | 0 |
| After-tax WACC | 5.4% | 7.5% |
Our DCF model projects cash flows over 5-year and 10-year horizons, with the following key assumptions:
| DCF Model | Fair Value | Enterprise Value | % from Terminal Value |
|---|---|---|---|
| 5-Year Growth | $8 | $548M | 90.0% |
| 10-Year Growth | $12 | $821M | 83.0% |
| 5-Year EBITDA | $2 | $148M | 62.8% |
| 10-Year EBITDA | $4 | $263M | 46.7% |
The DDM values a company based on its expected future dividend payments. We used two approaches:
EPV assesses a company's value based on its current normalized earnings power, assuming no growth.
| EPV Component | Value |
|---|---|
| Normalized Earnings | $15M |
| Discount Rate (WACC) | 7.5% - 5.4% |
| Enterprise Value | $198M - $273M |
| Net Debt | $(11)M |
| Equity Value | $209M - $284M |
| Outstanding Shares | 70M |
| Fair Value | $3 - $4 |
| Selected Fair Value | $3.53 |
| Metric | Value |
|---|---|
| Market Capitalization | $3713M |
| Enterprise Value | $3702M |
| Trailing P/E | 244.97 |
| Forward P/E | 237.38 |
| Trailing EV/EBITDA | 5.50 |
| Current Dividend Yield | 0.00% |
| Dividend Growth Rate (5Y) | 0.00% |
| Debt-to-Equity Ratio | 0.00 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
| Valuation Method | Weight | Weighted Value |
|---|---|---|
| Discounted Cash Flow (10Y) | 30% | $3.57 |
| Discounted Cash Flow (5Y) | 25% | $2.00 |
| Dividend Discount Model (Multi-Stage) | 20% | $2.30 |
| Dividend Discount Model (Stable) | 15% | $3.62 |
| Earnings Power Value | 10% | $0.35 |
| Weighted Average | 100% | $11.84 |
Based on our comprehensive valuation analysis, Enlabs AB's weighted average intrinsic value is $11.84, which is approximately 77.7% below the current market price of $53.10.
Key investment considerations:
Given these factors, we believe Enlabs AB is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.